It has been reported that MEF2D rearrangements can enhance its transcriptional activity and lymphoid transformation, thus contributing to the development of a high-risk leukemia (Gu et al. 2016; Yasuda et al. 2016). The gene discussed is MEF2D; the disease is leukemia.